CJC-1295 – With DAC (10mg)

What is CJC-1295 - With DAC (10mg)?

CJC-1295 - With DAC (10mg) is a synthetic peptide derived from growth hormone–releasing hormone (GHRH 1-29). Unlike MOD-GRF(1–29), CJC-1295 is a long-acting GHRH analog that includes a Drug Affinity Complex (DAC). The addition of the DAC facilitates reversible binding to circulating albumin, thereby extending its systemic persistence in experimental models and making it structurally and pharmacokinetically distinct from MOD-GRF(1–29). The compound is identified by:

• CAS Number: 863288-34-0
• Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3647.2 g/mol
• Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Mpa)-NH₂

The full sequence includes four amino acid substitutions:

• D-Ala at position 2, enhancing enzymatic resistance
• Gln at position 8
• Ala at position 15
• Leu at position 27

These substitutions, alongside the DAC modification, help CJC-1295 resist enzymatic degradation and extend its biological activity in research settings. Research-grade material is typically supplied at ≥99% purity and used in studies of somatotropic signaling dynamics.

What are the key features of CJC-1295 - With DAC (10mg)?

CJC-1295 - With DAC (10mg) is formulated to support extended pharmacokinetic investigations and peptide signaling research. Key features include:

• 10 mg lyophilized peptide per sterile research vial
• Purity ≥99%, verified by HPLC and mass spectrometry (MS)
• Modified GHRH(1–29) analog with four amino acid substitutions for stability:
  • D-Ala² for enzymatic resistance
  • Gln at position 8
  • Ala at position 15
  • Leu at position 27
• DAC modification designed to extend plasma half-life through albumin binding
• Suitable for long-acting GH/IGF-1 axis studies in in vitro and in vivo models
• Batch-specific Certificate of Analysis available
• The lyophilized format supports long-term storage stability and controlled reconstitution for laboratory procedures

For laboratory research use only.

How is CJC-1295 - With DAC (10mg) synthesized?

CJC-1295 - With DAC is produced via solid-phase peptide synthesis (SPPS). This method allows precise incorporation of the 29 amino acids, including specific substitutions that enhance structural stability and receptor interaction compared to native GHRH (1-29). The tetrasubstituted configuration has been studied for improved enzymatic resistance while maintaining biological activity in experimental systems. After chain assembly, a maleimide-functionalized beta-alanine moiety is conjugated to a lysine residue. This DAC component enables covalent attachment to circulating albumin via thiol-maleimide chemistry. The final product is purified by preparative high-performance liquid chromatography (HPLC), and its identity is confirmed by mass spectrometry (MS) to verify molecular weight and structural integrity. Analytical documentation ensures consistency across research batches.

What is CJC-1295 - With DAC (10mg) being studied for? What are its possible benefits?

CJC-1295 - With DAC has been studied for its ability to prolong endogenous GH and IGF-1 secretion in animal models and early-phase human investigations. In published research, single subcutaneous administrations in rodents and healthy adults have been associated with multi-day elevations in circulating GH and IGF-1 concentrations. Areas under investigation include:

• Endocrine axis modulation
• Sustained somatotropic signaling
• Protein metabolism and nitrogen balance
• Body composition dynamics in experimental settings
• Long-acting peptide pharmacokinetics

These findings are exploratory and focus on understanding hormonal regulation, metabolic adaptation, and mechanisms that extend peptide half-lives. Observed biological responses remain under investigation and are not established as therapeutic outcomes.

How does CJC-1295 - With DAC (10mg) work in research studies?

In laboratory models, CJC-1295 - With DAC acts by stimulating GHRH receptors in the anterior pituitary. This interaction activates intracellular signaling pathways that increase cyclic AMP (cAMP) production and promote pulsatile GH release. Elevated GH may subsequently influence hepatic IGF-1 production.   The DAC modification contributes to prolonged systemic exposure. By binding to circulating albumin, the peptide forms a temporary reservoir, allowing gradual release and sustained receptor interaction. This extended duration distinguishes it from short-acting GHRH analogs and supports long-term signaling studies.

What dosing information exists for CJC-1295 - With DAC (10mg)?

Dosing information for CJC-1295 - With DAC is derived exclusively from preclinical and early investigational studies. Reported experimental ranges include:

• Rodent models: 30–250 µg/kg administered subcutaneously
• Observed GH elevations lasting up to 6 days after a single dose
• IGF-1 increases sustained for approximately 9–11 days in certain studies
• In vitro pituitary cell assays, nanomolar concentrations are used to measure:
  • cAMP accumulation
  • Growth hormone secretion
  • Signal transduction activity over short time frames (15–60 minutes)

In early human research settings, single doses between 30–60 µg/kg have been evaluated for pharmacokinetic and endocrine response profiling. These findings describe controlled study conditions only. However, no established clinical dosing guidelines exist for CJC-1295 - With DAC (10mg).

How should CJC-1295 - With DAC (10mg) be stored and handled?

Proper storage is essential to maintain peptide stability:

• Store lyophilized peptide at ≤–20 °C for long-term preservation
• Shelf life: up to 24 months under recommended conditions
• Protect from light and moisture
• Room temperature exposure during shipping is acceptable
• After reconstitution, store at 2–8 °C for short-term use
• Avoid repeated freeze-thaw cycles
• Use aseptic laboratory technique during handling

Where can I read more research about CJC-1295 - With DAC (10mg)?

The following peer-reviewed publications provide foundational research on CJC-1295 and related GHRH analogs:

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
2. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
3. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
4. Thorner MO. The discovery of growth hormone-releasing hormone. J Neuroendocrinol. 2008;20(6):647-652. doi:10.1111/j.1365-2826.2008.01739.x

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.